ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, ...

Pemvidutide improves fibrosis markers, liver fat, lipids, weight, and blood pressure in patients with MASH at 1 year, phase 2b data show.

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or ...

Eli Lilly and Company today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) ...

Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate ...

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemiaMitapivat is now approved for thalassemia in the U.S., Sa ...

Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a third-generation ALK inhibitor, available in Europe ...

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent ...

After driving an hour from Barcelona-El Prat airport to the Familia Torres winery in Pacs del Penedès, it’s easy to understand the clamor for Catalonia. If there’s magic in the region, it’s in the ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Camera Bartolotta is set to seek a fourth term this November representing Pennsylvania’s 46th Senate District. The Associated ...